AmBisome Indications/Uses

AmBisome is indicated in adults and children aged 1 month to 18 years old.
AmBisome is indicated for the treatment of systemic mycotic infections due to organisms susceptible to this anti-infective, such as cryptococcosis, North American blastomycosis, disseminated candidiasis, coccidioidomycosis, aspergillosis, histoplasmosis, mucormycosis and in the treatment of some cases of American mucocutaneous leishmaniasis.
AmBisome is indicated for the treatment of fever of unknown origin (FUO) in neutropenic patients. In this context, FUO is defined as persisting fever, unresponsive to at least 96 hours of antibiotic treatment; it is highly indicative for a systemic fungal infection in this patient population. Before initiating AmBisome treatment, common viral, parasitic or mycobacterial infections should also be excluded as far as possible as causes for the observed FUO.
AmBisome is indicated as the primary therapy of visceral leishmaniasis in immunocompetent patients including both adults and children. In immunocompromised patients (e.g. HIV positive) AmBisome is also indicated as the primary therapy of visceral leishmaniasis.
This drug should not be used to treat the common clinically inapparent forms of fungal disease which show only positive skin or serologic tests.